The incoming presidential administration of 2025 should champion a policy position calling for strengthening of the connection between K-12 schools and community workplaces.
Small, fast grant programs are vital to supporting transformative research. By adopting a more flexible, decentralized model, we can significantly enhance their impact.
New solutions are needed to target diseases before they are life-threatening or debilitating, moving from retroactive sick-care towards preventative healthcare.
To help all American workers and strengthen the national economy, the next administration should establish a Sector-Focused Employment Training Initiative to coordinate and expand evidence-based sectoral employment training programs across the U.S. workforce
To improve program outcomes, federal evaluation officers should conduct “unmet desire surveys” to advance federal learning agendas and built agency buy-in.
At least 40% of Medicare beneficiaries do not have a documented AHCD. In the absence of one, medical professionals may perform major and costly interventions unknowingly against a patient’s wishes.
AI has transformative potential in the public health space, but innovation driven primarily by the private sector today may be exacerbating existing disparities by training models.
With targeted policy interventions, we can efficiently and effectively support the U.S. innovation economy through the translation of breakthrough scientific research from the lab to the market.
Innovations in artificial intelligence and robotics will allow us to accelerate the search process using foundation AI models for science research and automate much of the experimentation with robotic, self-driving labs.
The United States needs a strategic investment fund (SIF) to shepherd promising technologies in nationally vital sectors through the valley of death.
Standardizing support for Accessibility & Accommodations in federally funded research efforts would open opportunities for disabled scientists and their research programs.
The incoming administration must act to address bias in medical technology at the development, testing and regulation, and market-deployment and evaluation phases.